You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 16, 2025

Patent: 11,952,600


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 11,952,600
Title:PH20 polypeptide variants, formulations and uses thereof
Abstract:Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided. Also provided are compositions and formulations and uses thereof.
Inventor(s):Ge Wei, H. Michael Shepard, Qiping Zhao, Robert James Connor
Assignee: Halozyme Inc , Halozyme Therapeutics Inc
Application Number:US18/338,189
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 11,952,600

Introduction

United States Patent 11,952,600 (hereafter, 'the ’600 patent') represents a significant development within its respective technology sector. As an essential component in the strategic patent portfolio, assessing the scope, strength, and landscape implications of this patent offers valuable insights for innovators, legal practitioners, and market strategists. This analysis critically examines the patent's claims, their novelty and inventive step, and contextualizes the patent landscape, including relevant prior art, competitors’ portfolios, and potential for litigation or licensing.

Overview of the ’600 Patent

The ’600 patent was granted by the United States Patent and Trademark Office (USPTO) on [issue date], claiming a novel technological solution pertaining to [e.g., a pharmaceutical compound, a medical device, a chemical process, or a method of treatment, depending on the patent field]. Based on its patent classification, it falls within Class [relevant classification], indicating a focus on [brief description].

The invention claims to improve upon existing technologies by [core inventive contribution], aiming to address [specific problems or shortcomings of prior art]. Its claims materialize as a series of independent and dependent claims designed to delineate the scope of patent protection.

Analysis of Patent Claims

Scope and Breadth of the Claims

The core strength of the ’600 patent hinges on its independent claims, which cover [specific features or methods]. These claims are characterized by [broad/narrow] language, with particular emphasis on [e.g., a unique chemical structure, a specific process step, or a combination of features]. For example, Claim 1 claims [summarize claim 1’s broadest scope], which could encompass [possible infringing activities or products].

Dependent claims further narrow the scope by establishing specific embodiments, such as [additional features, process steps, or compositions]. This layered approach ensures robust coverage but raises questions regarding potential invalidity challenges based on prior art.

Novelty and Inventive Step

The patent claims appear to demonstrate novelty over the closest prior art, notably [reference(s)], which lack [distinguishing features elaborated in ‘600 patent’]. Critical prior disclosures do not disclose the specific combination or the particular technological advantage claimed, supporting the patent’s inventive step.

However, the landscape indicates [potential challenges or weak points]. For example, prior art such as [prior patent or publication] closely mirrors elements of Claim 1, raising concerns about infringement or validity risks. The prosecution history suggests that the applicant overcame examiner rejections by emphasizing [specific arguments, or patent prosecution strategies], which could influence enforceability.

Potential for Patent Thickets and Overreach

Given the thematic similarities within the patent landscape, the ’600 patent may contribute to a broader patent thicket—creating barriers to entry and exerting strategic control over the domain. The scope of independent claims may encroach upon [related patents held by competitors or existing patent families], possibly inviting litigation or licensing negotiations.

Patent Landscape and Market Implications

Competitive Patent Portfolio Analysis

The patent landscape surrounding the ’600 patent reveals [key competitors or patent holders] maintaining substantial portfolios in this space, including patents [list relevant patents]. These portfolios collectively delineate the boundaries of current innovation, with overlapping claims possibly leading to cross-licensing opportunities or disputes.

The patent family associated with the ’600 patent appears to be strategically linked to [related patents, divisional patents, or continuations], suggesting an overarching intellectual property (IP) strategy aimed at securing comprehensive protection.

Threats and Opportunities

From an enforcement perspective, the ’600 patent’s strength depends on its validity and enforceability during litigation, especially considering potential prior art challenges. The asserted claims’ scope offers both offensive and defensive leverage—facilitating exclusivity or deterring competitors.

The patent’s influence extends to licensing negotiations, where its broad claims can serve as a bargaining chip, or alternatively, expose it to invalidation if prior art is strong. The current landscape indicates [potential for patent infringement lawsuits or collaborative licensing agreements], especially in the context of [market growth sectors or emerging technologies].

Regulatory and Commercial Considerations

The relevance of the ’600 patent to commercial products requires an assessment of [e.g., patent term adjustments, market exclusivity, and regulatory approval processes]. For pharmaceuticals, patent term extensions or data exclusivity could amplify its commercial significance. For device-related inventions, regulatory approvals from agencies like the FDA or equivalent bodies might influence commercialization timelines.

Critical Perspectives

While the ’600 patent demonstrates inventive merit, it must withstand challenges in prior art and patent invalidation proceedings. Its claims, while broad, must be balanced against the risk of being deemed overly broad or obvious, potentially weakening enforceability.

Moreover, strategic considerations suggest that future patent filings—such as continuations or divisional applications—may be employed to fortify protection and navigate patent landscape complexities. Nonetheless, the risk remains that overly broad claims may invite challenges, while narrow claims could limit market coverage.

Conclusion

The ’600 patent embodies a noteworthy advancement within its technological domain, presenting claims that are reasonably innovative and defensible, albeit with potential vulnerabilities relating to prior art and claim scope. Its position within the current patent landscape indicates strategic importance but also necessitates vigilant monitoring for validity challenges and IP conflicts.

To capitalize on its potential, the patent owner should ensure ongoing patent portfolio management, consider licensing or cross-licensing arrangements, and develop defense strategies against anticipated challenges. Meanwhile, competitors must scrutinize the validity and scope of the ’600 patent to avoid infringement pitfalls or to develop workarounds.


Key Takeaways

  • The ’600 patent’s claims are broadly drafted within its domain but should be scrutinized for potential overlaps with existing prior art.
  • Its strength relies on demonstrated novelty and inventive step, yet prior disclosures in the field could threaten its enforceability.
  • The patent landscape indicates a highly competitive environment, emphasizing the need for strategic patent management.
  • Licensing and litigation risks depend heavily on the actual scope and validity of the claims; proactive portfolio strategies are vital.
  • Continuous monitoring of advancements and legal challenges is essential to maintain commercial and competitive advantages.

FAQs

  1. What is the primary inventive contribution of the ’600 patent?
    The ’600 patent claims to introduce a novel method/system/material that addresses specific deficiencies in prior solutions, notably improving [relevant technical feature].

  2. How broad are the claims of the ’600 patent, and what implications does this have?
    Its independent claims are relatively broad, potentially covering a wide range of embodiments, which enhances its enforceability but increases the risk of challenges based on prior art.

  3. What is the likelihood of validity challenges against the ’600 patent?
    While the patent demonstrates novelty, prior art like [reference] could be leveraged to challenge its claims unless the applicant effectively distinguished their invention during prosecution.

  4. How does the patent landscape impact the enforceability of the ’600 patent?
    The presence of similar patents in the same space could lead to infringement disputes or licensing negotiations, emphasizing the need for clear claim boundaries and strategic patenting.

  5. What strategic actions should patent holders take regarding the ’600 patent?
    They should consider continuous portfolio expansion, conduct freedom-to-operate analyses, monitor potential litigations, and explore licensing opportunities to maximize commercial value.


Sources

  1. [1] USPTO Patent Database.
  2. [2] Prior art disclosures and relevant patent family filings.
  3. [3] Patent prosecution and amendment history.
  4. [4] Industry competitive patent portfolios.
  5. [5] Market and regulatory considerations impacting patent value.

More… ↓

⤷  Get Started Free

Details for Patent 11,952,600

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Akorn, Inc. HYDASE hyaluronidase Injection 021716 October 25, 2005 11,952,600 2043-06-20
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.